Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094260 | 0.79 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2ADRB2XPO1 | |
| SCHEMBL20088497 | 0.78 | KDM4E (0.32) | KDM4E | |
| SCHEMBL20094275 | 0.78 | PDE10A (0.36) | ALDH1A1KDM4ESMN1; SMN2ADRB2XPO1 | |
| SCHEMBL20094357 | 0.75 | DHODH (0.40) | ALDH1A1KDM4ESMN1; SMN2ADRB2XPO1 | |
| SCHEMBL20094288 | 0.74 | XPO1 (0.34) | ALDH1A1KDM4EXPO1 | |
| SCHEMBL20094267 | 0.74 | CREBBP (0.34) | ALDH1A1XPO1 | |
| SCHEMBL20094342 | 0.73 | XPO1 (0.35) | ALDH1A1KDM4EADRB2XPO1 | |
| SCHEMBL20094632 | 0.72 | HTT (0.33) | KDM4E | |
| SCHEMBL20094270 | 0.69 | PDE10A (0.32) | XPO1 | |
| SCHEMBL20088519 | 0.69 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963851-B | Fused bicyclic pyridine compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-02 | — | — | US | disclosed |
| WO-2018080917-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | GRIN1, GRIN3A, GRM1 | ALDH1A1 1440/4885KDM4E 2891/4885SMN1; SMN2 2930/4885 |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN3A, GRM1 | ALDH1A1 1440/4885KDM4E 2891/4885SMN1; SMN2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.